van Lengerich, Bettina
Zhan, Lihong http://orcid.org/0000-0001-7772-9340
Xia, Dan
Chan, Darren
Joy, David http://orcid.org/0000-0001-9941-9538
Park, Joshua I.
Tatarakis, David
Calvert, Meredith
Hummel, Selina
Lianoglou, Steve http://orcid.org/0000-0002-0924-1754
Pizzo, Michelle E.
Prorok, Rachel
Thomsen, Elliot
Bartos, Laura M.
Beumers, Philipp
Capell, Anja
Davis, Sonnet S.
de Weerd, Lis
Dugas, Jason C.
Duque, Joseph
Earr, Timothy
Gadkar, Kapil
Giese, Tina
Gill, Audrey
Gnörich, Johannes
Ha, Connie
Kannuswamy, Malavika
Kim, Do Jin
Kunte, Sebastian T.
Kunze, Lea H. http://orcid.org/0000-0003-4669-2113
Lac, Diana
Lechtenberg, Kendra
Leung, Amy Wing-Sze
Liang, Chun-Chi
Lopez, Isabel
McQuade, Paul
Modi, Anuja
Torres, Vanessa O.
Nguyen, Hoang N. http://orcid.org/0000-0001-6608-7581
Pesämaa, Ida
Propson, Nicholas
Reich, Marvin
Robles-Colmenares, Yaneth
Schlepckow, Kai
Slemann, Luna
Solanoy, Hilda
Suh, Jung H.
Thorne, Robert G.
Vieira, Chandler
Wind-Mark, Karin
Xiong, Ken http://orcid.org/0000-0003-0334-7512
Zuchero, Y. Joy Yu
Diaz, Dolo
Dennis, Mark S.
Huang, Fen
Scearce-Levie, Kimberly http://orcid.org/0000-0003-0568-802X
Watts, Ryan J.
Haass, Christian http://orcid.org/0000-0002-4869-1627
Lewcock, Joseph W.
Di Paolo, Gilbert http://orcid.org/0000-0003-1032-1265
Brendel, Matthias http://orcid.org/0000-0002-9247-2843
Sanchez, Pascal E. http://orcid.org/0000-0002-2620-5165
Monroe, Kathryn M. http://orcid.org/0000-0002-6901-1176
Article History
Received: 14 April 2022
Accepted: 29 November 2022
First Online: 12 January 2023
Competing interests
: All authors, except P.M.Q., S.H., P.B., A.C., J.G., S.T.K., L.H.K., I.P., K.S., L.S., L.D.W., K.W.-M., M.R., L.M.B., M.B. and C.H., are full-time employees and/or shareholders of Denali Therapeutics. C.H. is a collaborator of Denali Therapeutics, participated on one advisory board meeting of Biogen and received a speaker honorarium from Novartis and Roche. C.H. is chief advisor of ISAR Bioscience and a member of the advisory board of AviadoBio. P.M.Q. is a full-time employee of Takeda Pharmaceuticals, Inc., a clinical development partner of Denali Therapeutics. This work has been described, in part, in pending patent applications.